Targeting growth factor receptors: Integration of novel therapeutics in the management of head and neck cancer

Current Opinion in Oncology

Volumn 13, Issue 3, 2001, Pages 168-175

  Lango, Miriam N ^a   Shin, Dong Moon ^a,b   Grandis, Jennifer Rubin ^a,b  

^a Department of Otolaryngology ^*  (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL TRANSFORMATION; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0035026164     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200105000-00007     Document Type: Review

References (105)

1. 1 Harris AL, Nicholson S, Sainsbury JR, et al.: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989, 34:123-131.
2. 2 Fox SB, Smith K, Hollyer J, et al.: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994, 29:41-49.
3. 3 Toi M, Osaki A, Yamada H, et al.: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 1991, 27:977-980.
4. 4 Toi M, Nakamura T, Mukaida H, et al.: Relation between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 1990, 65:1980-1984.
5. 5 Nicholson S, Wright C, Sainsbury JR, et al.: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure, J Steroid Biochem Mol Biol 1990, 37:811-814.
6. 6 Nicholson S, Sainsbury JR, Halcrow P, et al.: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989, i:182-185.
7. 7 Lamerz R: Role of tumor markers, cytogenetics. Ann Oncol 1999, 10(suppl 4):145-149.
8. 8 Krupski T, Moskaluk C, Boyd JC, et al.: A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. BJU Int 2000, 85:1027-1032.
9. 9 Chow NH, Liu HS, Lee El, et al.: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997, 17:1293-1296.
10. 10 Liukkonen T, Rajala P, Raitanen M, et al.: Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999, 36:393-400.
11. 11 Nguyen PL, Swanson PE, Jaszcz W, et al.: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: a multivariate survival analysis. Am J Clin Pathol 1994, 101:166-176.
12. 12 Ohsaki Y, Tanno S, Fujita Y, et al.: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000, 7:603-607.
13. 13 Veale D, Kerr N, Gibson GJ, et al: The relation of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993, 68:162-165.
14. 14 Hurtt MR, Mossy J, Donovan-Peluso M, et al.: Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992, 51:84-90.
15. 15 Zhu A, Shaeffer J, Leslie S, et al.: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996, 34:809-815.
16. 16 Korshunov A, Golanov A, Sycheva R, et al.: Prognostic value of tumor associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 1999, 52:574-580.
17. 17 Yamanaka Y, Friess H, Kobrin MS, et al.: The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi 1992, 59:51-61.
18. 18 Yamanaka Y, Friess H, Kobrin MS, et al.: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993, 13:565-569.
19. 19 Dong M, Nio Y, Guo KJ, et al.: Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998, 18:4613-4619.
20. 20 Grandis JR, Zeng Q, Tweardy DJ: Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med 1996, 2:237-240.
21. 21 Brandt R, Eisenbrandt R, Leenders F, et al.: Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000, 19:2129-2137. Tissue-specific EGFR overexpression in a transgenic mouse model results in impaired mammary gland development, reducing the differentiation potential of the mammary epithelium and inducing epithelial cell transformation.
22. 22 Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53:3579-3584.
23. 23 Grandis JR, Melhem MF, Gooding WE, et al.: Levels of TGF·alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
24. 24 Shin DM, Ro JY, Hong WK, et al.: Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis, Cancer Res 1994, 54:3153-3159.
25. 25 Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
26. 26 Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994, 73:2359-2365.
27. 27 Stal O, Sullivan S, Wingren S, et al.: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995, 31A:2185-2190.
28. 28 Torre EA, Salimbeni V, Fulco RA: The erbB 2 oncogene and chemotherapy: a mini-review. J Chemother 1997, 9:51-55.
29. 29 Muss HB, Thor AD, Berry DA, et al.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266.
30. 30 Katsumata M, Okudaira T, Samanta A, et al.: Prevention of breast tumor development in vivo by downregulation of the p185neu receptor. Nat Med 1995, 1:644-648.
31. 31 Klapper LN, Glathe S, Vaisman N, et al.: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999, 96:4995-5000. ErbB receptor-mediated signal transduction on ligand binding is augmented in the presence of erbB2, implying that erbB2 serves as a shared receptor subunit of all ErbB-specific growth factors. Thus, oncogenicity of ErbB-2 in human epithelia may not rely on the existence of a specific ligand but rather on its ability to act as a coreceptor.
32. 32 Pastorino U, Sozzi G, Miozzo M, et al.: Genetic changes in lung cancer. J Cell Biochem Suppl 1993, 17F:237-248.
33. 33 Tagliabue E, Centis F, Campiglio M, et al.: Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer 1991, 47:933-937.
34. 34 Kern JA, Schwartz DA, Nordberg JE, et al.: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990, 50:5184-5187.
35. 35 Jaehne J, Urmacher C, Thaler HT, et al.: Expression of Her2/neu oncogene product p185 in correlation to clinicopathologic and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992, 118:474-479.
36. 36 Albino AP, Jaehne J, Altorki N, et al.: Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. Eur J Surg Oncol 1995, 21:56-60.
37. 37 Nakajima M, Sawada H, Yamada Y, et al.: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
38. 38 Gurel S, Dolar E, Yerci O, et al.: The relation between c-erbB-2 oncogene expression and clinicopathologic factors in gastric cancer. J Int Med Res 1999, 27:74-78.
39. 39 Allgayer H, Babic R, Gruetzner KU, et al.: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000, 18:2201-2209.
40. 40 Meden H, Kuhn W: Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997, 71:173-179.
41. 41 Kiguchi K, Bol D, Carbajal S, et al.: Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 2000, 19:4243-4254. Overexpressian of wild-type rat erbB2 in the basal layer of epidermis of transgenic mice led to the development of spontaneous papillomas, which transformed into squamous cell carcinomas. Elevations in EGFR and erbB2 protein as well as erbB2:EGFR and erbB2:erbB3 heterodimers were observed in skin of the erbB2 transgeníc mìce, Phosphotyrosine levels of the EGFR, erbB2, and erbB3 proteins were also elevated.
42. 42 Beckhardt RN, Kiyokawa N, Xi L, et al.: HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995, 121:1265-1270.
43. 43 Field JK, Spandidos DA, Yiagnisis M, et al.: C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992, 12:613-619.
44. 44 Craven JM, Pavelic ZP, Stambrook PJ, et al.: Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992, 12:2273-2276.
45. 45 Xia W, Lau YK, Zhang HZ, et al.: Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997, 3:3-9.
46. 46 Kraus MH, Fedi P, Starks V, et al.: Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci U S A 1993, 90:2900-2904.
47. 47 Lyne JC, Melhem MF, Finley GG, et al.: Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997, 3:21-30.
48. 48 Cohen BD, Kiener PA, Green JM, et al.: The relation between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 1996, 271:30897-30903.
49. 49 Ciardiello F, Kim N, Sacki T, et al.: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A 1991, 88:7792-7796.
50. 50 Knowlden JM, Gee JM, Seery LT, et al.: c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998, 17:1949-1957.
51. 51 Shintani S, Funayama T, Yoshihama Y, et al.: Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett 1995, 95:79-83.
52. 52 Sawyer C, Hiles I, Page M, et al.: Two erbB-4 transcripts are expressed in normal breast and in most breast cancers. Oncogene 1998, 17:919-924.
53. 53 Srinivasan R, Benton E, McCormick F, et al.: Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res 1999, 5:2877-2883. C-erbB3 receptor was weakly expressed in normal endometrium. The c-erbB4 receptor and all of the ligands examined, neuregulin alpha, neuregulin beta, and betacellulin, were expressed at significantly higher levels in the secretory as compared with the proliferative phase of the menstrual cycle, In endometrial adenocarcinoma, overexpression of c-erbB3, c-erbB4, and betacellulin with underexpression of neuregulin a as compared with normal controls was observed.
54. 54 al Moustafa AE, Alaouì-Jamali M, Paterson J, et al.: Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. Anticancer Res 1999, 19:481-486.
55. 55 Kew TY, Bell JA, Pinder SE, et al.: c-erbB-4 protein expression in human breast cancer. Br J Cancer 2000, 82;1163-1170.
56. 56 Tang CK, Concepcion XZ, Milan M, et al.: Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo, Cancer Res 1999, 59:5315-5322.
57. 57 Ibrahim SO, Vasstrand EN, Liavaag PG, et al.: Expression of c-erbB protooncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997, 17:4539-4546.
58. 58 Xia W, Lau YK, Zhang HZ, et al.: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999, 5:4164-4174. Expression of EGFR, Her2-neu, and Her3 was significantly associated with the presence of lymph node and distant metastasis in patients with oral SCC. The expression of all EGFR members was significantly associated with shortened patient survival, and the combination of Her2, Her3, and EGFR but not Her4 significantly improved the predicting power. The expression level of Her2-neu was significantly correlated with that of EGFR or Her3. Similar coexpression patterns were also observed in three oral SCC cell lines studied.
59. 59 Bei R, Masuelli L, Moriconi E, et al.: Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 1999, 18:1267-1275. Immunoreactivity against all four ErbB receptors was detected in 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2, followed by EGFR, ErbB3, and ErbB4. Approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors, including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2, and ErbB3.
60. 60 Klapper LN, Kirschbaum MH, Sela M, et al.: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000, 77:25-79.
61. 61 Yang H, Jiang D, Li W, et al.: Defective cleavage of membrane bound TGFalpha leads to enhanced activation of the EGF receptor in malignant cells. Oncogene 2000, 19:1901-1914. A defective cleavage pattern for the TGF-α precursor resulting in retention of partially processed TGF-α on the cell surface of two colon carcinoma cell lines. The membrane-associated TGF-α induced higher phosphorylation of EGFR on the cell surface of adjacent cells than equivalent levels of mature TGF-α and caused a slower internalization of activated EGFR relative to the internalization of the soluble TGF-α/EGFR complexes. The tethered TGF-α was resistant to the ability of protein-tyrosine phosphatases to reduce EGFR tyrosine phosphorylation. Higher activation of Grb2, SHC, and Erk downstream mediators of EGFR signaling was observed.
62. 62 Grandis JR, Chakraborty A, Zeng Q, et al.: Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 1998, 69:55-62.
63. 63 Fry DW: Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999, 82:207-218. Significant progress has been made in the area of EGFR tyrosine kinase inhibitors, and new structural classes have emerged that exhibit improvements with regard to potency, specificity, and in vitro and in vivo activity. Recently, further advancements in this field have been made whereby very specific, irreversible inhibitors of the EGFR family have been synthesized that provide unique pharmacologic properties.
64. 64 Fedi P, Pierce JH, di Fiore PP, et al.: Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994, 14:492-500.
65. 65 Brandt BH, Roetger A, Dittmar T, et al.: c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 1999, 13:1939-1949. Cell migration is linked to c-erbB-2 signaling in breast cancer cells. Cell lines with c-erbB-2 and EGFR expression and transphosphorylation activity display increased endothelial invasiveness in an endothelial-extracellular matrix model mimicking a capillary vessel wall in vitro. On the molecular level, there is cross-talk between the transmembrane c-erbB-2 and the actin cytoskeleton at multiple levels.
66. 66 Zhang K, Sunday J, Liu N, et al.: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 1996, 271:3884-3890.
67. 67 Bromberg J, Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473. The STAT proteins (in particular STATs 1, 3, and 5) may mediate growth factor dysregulation characteristic of many malignancies. STAT1 plays an important role in growth arrest and in promoting apoptosis and is implicated as a tumor suppressor, whereas STATs 3 and 5 are involved in promoting cell cycle progression and cellular transformation and in preventing apoptosis.
68. 68 Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225. This paper reviews our current understanding of cell signaling by receptor tyrosine kinases. Mechanisms of receptor activation are described and an overview of signaling pathways is provided.
69. L expression in head and neck tumors, supporting the role of STAT3 as an oncogene.
70. 70 Lou W, Ni Z, Dyer K, et al.: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000, 42:239-242.
71. 71 Nielsen M, Kaestel CG, Eriksen KW, et al.: Inhibition of ccnstitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 1999, 13:735-738.
72. 72 Frank DA: STAT signaling in the pathogenesis and treatment of cancer. Mol Med 1999, 5:432-456.
73. 73 Fernandes A, Hamburger AW, Gerwin BI: ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 1999, 83:564-570. STAT3 is constitutively activated in non-small cell lung cancer cell lines by the TGF-α stimulation of the ErbB1/2 heterodimer complex. ErbB1 was required but not sufficient for the TGF-α-induced activation of STATs. Inhibition of ErbB2 kinase activity by tyrphostin AG825 prevented the constitutive activation of STAT3 in the TGF-α-producing, ErbB1-expressing cell line. Therefore ErbB-2 kinase activity is required for constitutive STAT3 activation resulting from an autocrine ErbB1/TGF-α loop.
74. 74 Mui AL: The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci 1999, 55:1547-1558.
75. 75 Huang M, Page C, Reynolds RK, et al.: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 2000, 79:67-73.
76. 76 Grandis JR, Drenning SD, Chakraborty A, et al.: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998, 102:1385-1392.
77. 77 Grandis JR, Zeng Q, Drenning SD: Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 2000, 110(5 part 1):868-874.
78. L expression in a head and neck xenograft model.
79. 79 Wells A, Ware MF, Allen FD, et al.: Shaping up for shipping out: PLCgamma signaling of morphology changes in EGF-stimulated fibroblast migration. Cell Motil Cytoskeleton 1999, 44:227-233.
80. 80 Azemar M, Schmidt M, Arlt F, et al.: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 2000, 86:269-275. The antitumoral activity of recombinant single-chain antibody toxins fused to a truncated pseudomonal exotoxin and specific for ErbB2 and EGFR inhibited growth of HNSCC cell lines. In a nude mouse tumor model, intratumoral injection of the antibody toxins resulted in the rapid regression of HNSCC tumor xenografts, leading to the cure of up to 50% of the animals.
81. 81 Pavlovskis OR, Voelker FA, Shackelford AH: Pseudomonas aeruginosa exotoxin in mice: histopathology and serum enzyme changes. J Infect Dis 1976, 133:253-259.
82. 82 Schumann J, Angermuller S, Bang R, et al.: Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J Immunol 1998, 161:5745-5754.
83. 83 Morgan AC Jr, Manger R, Pearson JW, et al.: Immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkeys, and man. Cancer Detect Prev 1991, 15:137-143.
84. 84 Goldberg MR, Heimbrook DC, Russo P, et al.: Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995, 1:57-61.
85. 85 Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
86. 86 Pegram MD, Lipton A, Hayes DF, et al.: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 16:2659-2671.
87. 87 Pegram M, Hsu S, Lewis G, et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251. Recombinant human monoclonal antibody Her2 in combination with cisplatin, thiotepa, and etoposide caused synergistic growth inhibition of breast cancer cell lines. Additive cytotoxic effects were observed with doxorubicin, paclitaxel, methotrexate, and vinblastine. 5-Fluorouracil was found to be antagonistic with recombinant human monoclonal antibody Her2 in vitro. Treatment of human breast cancer xenografts in athymic nude mice was consistent with in vitro studies.
88. 88 Ewer MS, Gibbs HR, Swafford J, et al.: Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 1999, 26(4 suppl 12):96-101.
89. 89 Prewett M, Rockwell P, Rockwell RF, et al.: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996, 19:419-427.
90. 90 Goldstein NI, Prewett M, Zukiys K, et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
91. 91 Hoffmann T, Hafner D, Ballo H, et al.: Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 1997, 17:4419-4425.
92. 92 Rubin Grandis J, Chakraborty A, Melhem MF, et al.: Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997, 15:409-416.
93. 2-M), redistribution of DNA-dependent protein kinase from the nucleus to the cytosol, inhibiting postradiation damage repair, and inhibition of angiogenesis with decreased expression of tumor angiogenesis markers, including vascular endothelial growth factor and factor VIII.
94. 94 Milas L, Mason K, Hunter N, et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701-708. Tumor radioresponse was increased in HNSCC mouse xenografts also treated with C225. Histologic analyses of tumors revealed that C225 caused an increase in central tumor necrosis with hemorrhage and vascular thrombosis when combined with radiotherapy. In addition, C225 induced heavy tumor infiltration with granulocytes, increased tumor cell terminal differentiation, and inhibited tumor angiogenesis.
95. 95 Mendelsohn J, Shin DM, Donate N: Phase I study of chimerized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients with recurrent head and neck squamous cell carcinoma (SCC) [abstract]. Proc Am Soc Clin Oncol 1999, 18:339a.
96. 96 Ezekiel MP, Bonner JA, Robert F: Phase I trial of chimerized anti-epidermal growth factor receptor (EGFR) antibody in combination with once-daily or twice-daily irradiation for locally advanced head and neck malignancies [abstract]. Proc Am Soc Clin Oncol 1999, 18:388a.
97. 97 Zaman GJ, Vink PM, van den Doelen AA, et al.: Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem Pharmacol 1999, 57:57-64.
98. 98 Smaill JB, Palmer BD, Rewcastle GW, et al.: Tyrosine kinase inhibitors: 15, 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999, 42:1803-1815.
99. 99 Showalter HD, Bridger AJ, Zhou H, et al.: Tyrosine kinase inhibitors: 16. 6,5,6-tricyclic benzothieno3,2-dpyrimidines and pyrimido5,4-b-and -4,5-bindoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase. J Med Chem 1999, 42:5464-5474.
100. 100 Noonberg SB, Benz CC: Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticanoer agents. Drugs 2000, 59:753-767.
101. 101 Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82:241-250.
102. 102 Bridges AJ: The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999, 6:825-843.
103. 103 He Y, Zeng O, Drenning SD, et al.: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998, 90:1080-1087.
104. 104 Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor, Clin Cancer Res 2000, 6:2053-2063. A dose-dependent synergistic growth inhibition in vitro was observed when multiple epithelial tumor cell lines were treated with each cytotoxic drug and ZD-1839. The combined treatment markedly enhanced apoptotic cell death induced by single-agent treatment. The combined treatment with topotecan, raltiterxed, or paclitaxel, and ZD-1839 produced tumor growth arrest in tumor xenografts; however, growth resumed at a rate similar to controls several weeks after completing treatment.
105. 103 Endo S, Zeng Q, He Y, et al.: TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther 2000, 7:1906-1914.